<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648176</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)501/2019</org_study_id>
    <nct_id>NCT04648176</nct_id>
  </id_info>
  <brief_title>Application of MOSES Technology in BPH</brief_title>
  <official_title>Evaluation of Surgical and Functional Results of the Application of MOSES Technology in the Holmium Laser Prostate Enucleation as a Treatment for Tract Symptoms Lower Urinary Secondary to Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators intend to compare the surgical and functional results of two&#xD;
      different modalities of the use of the Holmium laser in prostate enucleation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators intend to compare the surgical and functional results of two&#xD;
      different modalities of the use of the Holmium laser in prostate enucleation using MOSES&#xD;
      technology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>24 hours after the surgery</time_frame>
    <description>Hemoglobin change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enucleation time</measure>
    <time_frame>during the surgery</time_frame>
    <description>Enucleation time change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis time</measure>
    <time_frame>during the surgery</time_frame>
    <description>Hemostasis time change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morcellating time</measure>
    <time_frame>during the surgery</time_frame>
    <description>Morcellating time change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery time</measure>
    <time_frame>during the surgery</time_frame>
    <description>Surgery time change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irrigated volume of serum</measure>
    <time_frame>during the surgery</time_frame>
    <description>Irrigated volume of serum change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>one month after the surgery</time_frame>
    <description>difference of complication rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary tract infection</measure>
    <time_frame>one month after the surgery</time_frame>
    <description>urinary tract infection rate differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lower urinary tract symptoms</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>lower urinary tract symptoms rate differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sexual function</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>sexual function differences</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>HoLEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>m-HoLEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moses technology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Moses technology</intervention_name>
    <description>Using Holmium laser with Moses technology or conventional one</description>
    <arm_group_label>HoLEP</arm_group_label>
    <arm_group_label>m-HoLEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostatic volume between 70-200cc&#xD;
&#xD;
          -  Acceptance to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous urethra stricture&#xD;
&#xD;
          -  Previous prostate surgery&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Bladder tumor&#xD;
&#xD;
          -  Neurological disease with repercussion in the lower urinary tract.&#xD;
&#xD;
          -  Severe psychiatric illness&#xD;
&#xD;
          -  Inability of the patient to consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Placer Santos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebrón University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrià Piñero Zomeño, MD</last_name>
    <phone>934893000</phone>
    <phone_ext>6370</phone_ext>
    <email>adria.pinero@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrià Piñero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Placer Santos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alonso Narváez Barros, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enric Miret Alomar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Morote Robles, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrià Piñero Zomeño, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laser</keyword>
  <keyword>Holmium</keyword>
  <keyword>HoLEP</keyword>
  <keyword>Moses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

